Analyst firms · Leerink Partners · SPRB
Leerink Partners SPRB price target and rating history
Spruce Biosciences Inc. (SPRB) · Health Care
Leerink Partners rates Spruce Biosciences Inc. (SPRB) Outperform with a $160 price target, as of its latest action on Dec 3, 2025. It has published 4 rating actions on SPRB since November 2021, including 1 upgrade and 3 downgrades. Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Leerink Partners's $160 is 4% above that.
- Current rating
- Outperform
- Price target
- $160
- Median target, all firms
- $154.50
- Actions on SPRB
- 4
Leerink Partners price target on SPRB
Every Leerink Partners rating on SPRB
- Dec 3, 2025
- Mar 14, 2024
- Nov 16, 2021
- Nov 16, 2021
How other firms rate SPRB
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $149 | Sep 17, 2026 |
| B. Riley Securities | Buy | $160 | Jul 13, 2026 |
| Guggenheim | Buy | $123 | Jun 16, 2026 |
| Craig-Hallum | Buy | $140 | Apr 27, 2026 |
| Oppenheimer | Outperform | $283 | Dec 23, 2025 |
| Leerink Partners | Outperform | $160 | Dec 3, 2025 |
Questions about Leerink Partners and SPRB
- What is Leerink Partners's price target for SPRB?
- Leerink Partners's latest stated price target for Spruce Biosciences Inc. (SPRB) is $160, from its action on Dec 3, 2025.
- What is Leerink Partners's rating on SPRB?
- Leerink Partners rates SPRB Outperform, a bullish rating, as of Dec 3, 2025.
- When did Leerink Partners last change its view on SPRB?
- On Dec 3, 2025, Leerink Partners upgrades to Outperform from Market Perform, price target $160.
- How does Leerink Partners's SPRB target compare with other analysts?
- Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Leerink Partners's $160 is 4% above that.
More SPRB rating histories
All Leerink Partners ratingsSPRB news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.